Business Context and Reporting Period
The supplied filing is Renovaro Inc.’s unaudited Form 10-Q for the quarter and six months ended December 31, 2023, filed February 14, 2024. The request metadata identifies “Lunai Bioworks Inc.” and “2023 Q2,” which does not match the filing text. Renovaro is a pre-revenue biotechnology company developing cell and gene therapies for oncology, HIV and HBV.
During the period, management prioritized the RENB-DC11 oncology program and an HIV therapeutic vaccine, while deprioritizing certain other programs. The company completed its acquisition of GEDi Cube on February 13, 2024, after the reporting date.
Key Financial Metrics
| Metric | Three months ended December 31, 2023 | Six months ended December 31, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $4.27 million | $13.15 million |
| Operating loss | $4.27 million | $13.15 million |
| Net loss | $4.53 million | $13.70 million |
| Basic and diluted loss per share | $0.07 loss | $0.21 loss |
| Net cash used in operating activities | Not presented for the quarter | $5.92 million |
The company reported no revenue, gross profit or operating margin because it has not commercialized any products. Cash and cash equivalents were $243,980 at December 31, 2023, compared with $1.87 million at June 30, 2023. Total assets were $58.02 million, including $42.61 million of indefinite-lived license-related intangible assets and $11.64 million of goodwill.
Total liabilities were $14.42 million, including $3.94 million of notes payable, $2.57 million of convertible notes payable, $5.58 million of trade accounts payable and $1.67 million of lease liabilities and other current liabilities. The company reported a working capital deficit of $11.36 million and an accumulated deficit of $257.73 million.
Cash used in investing activities was $1.12 million, primarily reflecting $1.05 million of notes receivable issued to GEDi Cube. Financing activities provided $5.41 million, including proceeds from promissory notes, a $2.0 million private placement and warrant exercises.
Material Changes Versus the Prior Comparable Period
- Six-month operating expenses increased 14% to $13.15 million from $11.56 million. General and administrative expense increased 39% to $11.91 million, primarily due to $4.47 million of non-cash consulting fees, while research and development expense decreased 60% to $1.19 million as spending on discontinued candidates declined.
- Quarterly operating expenses decreased 2%, but quarterly net loss increased 2% to $4.53 million because of higher interest expense.
- Six-month net loss increased 13% to $13.70 million. The prior-year period included a $419,182 loss on extinguishment of contingent consideration; the current period included a $120,018 loss on extinguishment of debt.
- Cash declined 87% from June 30, 2023, while total liabilities increased 22% to $14.42 million.
- The company issued 561,010 Series A Convertible Preferred shares, initially convertible into 5.61 million common shares, and issued warrants to purchase 2.81 million common shares in connection with an August 2023 private placement and debt conversion.
- Common shares outstanding increased to 67.22 million at December 31, 2023, from 63.70 million at June 30, 2023. As of February 14, 2024, the filing reported 143.67 million common shares outstanding, largely reflecting the post-period GEDi Cube transaction.
Guidance, Outlook, Risks and Unusual Items
- Management expects to complete RENB-DC11 IND-enabling activities in the second half of 2024 and, if successful, begin human clinical trials in the second half of 2024. These are forward-looking objectives, not assurances.
- Management expects a possible pre-IND request for RENB-HV12 in the second half of 2024 and potential Phase 1 activity by mid-to-late 2025. RENB-HV21 is not expected to advance to an IND or clinical trial in the medium to long term.
- The company disclosed substantial doubt about its ability to continue as a going concern for one year after issuance of the financial statements. Continued operations depend on regulatory success, additional debt or equity financing and eventual profitability.
- Management warned that financing may be unavailable or available only on unfavorable terms, and equity financing could materially dilute existing shareholders. Without additional funding, operations could be materially reduced or suspended.
- The filing identified ineffective disclosure controls and a material weakness related to insufficient resources for complex accounting matters. Management expects the deficiency to continue until sufficient capital is available to hire additional accounting personnel.
- Existing debt includes 12% convertible notes, a $3.0 million remaining secured promissory note balance, and short-term bridge financing. Several obligations matured or were extended shortly after period-end, including a $1.0 million bridge loan extended to March 1, 2024.
- The company is involved in securities class action, derivative, contract and other litigation. Claimed damages are generally unspecified, and the company states that it cannot predict the outcomes.
- The GEDi Cube acquisition closed after quarter-end. The company issued 70.83 million restricted common shares as closing consideration, resulting in the sellers holding approximately 49% of common stock immediately after closing and conversion of the Series A Preferred shares.
- No additional impairment was recorded during the six months ended December 31, 2023, although the company recorded an $18.96 million impairment of its HIV license-related IPR&D asset in fiscal 2023.
Most Important Facts to Verify
- Confirm the intended issuer and period: the supplied text is for Renovaro Inc., not Lunai Bioworks Inc., and covers the quarter ended December 31, 2023.
- Assess near-term liquidity against the $243,980 cash balance, $11.36 million working capital deficit and upcoming debt maturities.
- Review the terms, conversion rights and dilution potential of the convertible notes, Series A Preferred shares, warrants and post-period GEDi Cube share issuance.
- Evaluate whether additional financing can be obtained and whether the going-concern uncertainty has been resolved.
- Monitor RENB-DC11 regulatory and clinical milestones, including the timing and funding of IND-enabling work.
- Review the material weakness in disclosure controls and any remediation disclosed in subsequent filings.
- Track the pending litigation and the potential financial or licensing consequences of the company’s claims and defendants’ cross-claims.